Related Experiment Video
Updated: Feb 25, 2026
The Dyspepsia Educational Tool As a Novel Aid in Dyspepsia Management
Published on: June 29, 2019
Impact of itopride on functional dyspepsia symptom progression: a multicenter noninterventional postregistration
Jiri Dolina1, Jan Tack2, Serhiy Forostyak3
1Department of Gastroenterology and Internal Medicine, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, 625 00, Czech Republic.
Background:
Functional dyspepsia (FD) is a prevalent condition characterized by symptoms such as postprandial fullness, early satiety, and epigastric pain, which significantly affect daily activities and quality of life.
Objectives:
This study aimed to assess the effectiveness of itopride hydrochloride, a prokinetic agent, in reducing the severity of these symptoms among patients with FD.
Design:
In this noninterventional, observational, post-authorization, prospective, multicenter study (without placebo or comparator) 339 patients with FD were treated with itopride and followed over a period of 12 weeks. The study clinical protocol ITO-NPS-01-PMCS-2021 was approved by the Ethical Committee of the University Hospital Brno and Faculty of Medicine, Masaryk University, Brno (ORG No: 100022981/LOC No:100031711), and reported to the Czech State Institute of Drug Control (identifier: 2110140000) following local legislation.
Methods:
The patients' symptoms were quantified at baseline, 3-6 weeks, and 7-12 weeks using the modified "Leuven Postprandial Distress Scale." Statistical analysis involved the Wilcoxon test, Mann-Whitney test, and Kruskal-Wallis test, focusing on changes in symptom scores and following potential adverse effects (AEs) over time.
Results:
Itopride hydrochloride treatment resulted in a statistically significant median reduction in symptom severity scores from baseline to the first and second follow-up assessments. The scores decreased by 5 points at the first follow-up and by 8 points at the second follow-up across all FD patient subgroups, regardless of age and gender. The study also observed minimal AEs, with only 2% of patients experiencing mild symptoms.
Conclusion:
Itopride appears to be a safe and effective treatment for reducing symptom severity in patients with FD. The findings support the use of itopride in clinical settings, providing evidence of its benefit in managing this challenging condition. This study brings additional clinical knowledge from the eastern European population (Czechs) to data published by the ROME IV foundation with various cohorts of patients with FD and its results further demonstrate the long-term benefits and safety profile of itopride with minimal non-AEs.
Related Concept Videos
01:17Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
01:21Drugs for Treatment of Constipation-Predominant IBS
01:30Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
01:28Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
01:29Gastroesophageal Reflux Disease II: Clinical Features and Management
Clinical Manifestations
GERD presents itself in a multitude of ways, with symptoms varying from person to person. The hallmark symptoms are...